Scientists Are Creating a Molecular Trap to Fight Cancer
Global oncology is experiencing a turning point. This technology, PROTAC (proteolysis targeting chimera), is a method that physically removes proteins responsible for cancer cell division and survival, harnessing the body's natural cleansing systems.
Traditional chemotherapy often attacks all rapidly dividing cells in the body. A new discovery is a game-changer: scientists have learned to use the cell's internal "shredder" against the tumor itself. Instead of injecting toxic substances, we program the cancer cell to self-destruct its key components.
The method works like a high-precision sniper: it "targets" only those proteins that make the tumor aggressive, forcing the cell to destroy its own defenses. This makes the disease visible and vulnerable to our immune system.
The pioneers of this approach are Professor Craig Crews of Yale University and Raymond Deshaies of Caltech. Their research in targeted protein degradation (TPD) has become the main hope for modern therapy.
"We don't simply block the activity of the cancer protein. We force the cell to physically degrade it," Professor Crews notes.
Latest data: According to reports published in Nature Communications and on ScienceDaily on April 8, 2026, PROTAC technology has successfully completed trials against specific oncoproteins previously considered resistant to treatment. This paves the way for the development of next-generation drugs for the treatment of prostate, breast, and blood cancers.
How It Works
It's based on the ubiquitin-proteasome pathway, the discovery of which earned a Nobel Prize. PROTAC technology directs this natural process:
Tagging: A targeting molecule locates the oncoprotein and places a "black mark" on it.
Recognition: A cellular organelle, the proteasome (our "molecular shredder"), recognizes this mark.
Disposal: The proteasome draws the oncoprotein in and breaks it down into harmless amino acids.
Institutes and Publications
Leading global centers are working on the project:
Yale Center for Molecular Discovery (development of the PROTAC platform).
Dana-Farber Cancer Institute (clinical trials in oncology).
Nature Medicine (up-to-date safety data: nature.com/articles/s41591-026).
For us, ordinary readers, this is a signal that medicine is moving away from fighting "consequences" and toward managing biological processes. The versatility of the method offers hope not only in oncology but also in the treatment of neurodegenerative diseases and age-related brain changes (Alzheimer's and Parkinson's), where the main problem is also "malformed" proteins.
